News

Clinical Trials

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Edward Kim | Equities.com |

The AstraZeneca deal continues to be a good one for Innate Pharma, year after year.


Johnson & Johnson Says Booster Dose of COVID-19 Vaccine Generates Strong Immune Response

Kimberly Redmond | Equities.com |

Johnson & Johnson (NYSE: JNJ) said a booster shot of its single-dose COVID-19 vaccine generated a promising immune response among participants in early-stage clinical trials.

In a press release Wednesday, the pharmaceutical company said that trial participants who received a booster shot had a “nine-fold” increase of virus-fighting antibodies compared to what was observed four weeks after the initial dose.


Novartis To Launch New Phase 3 Study To Expand Use of Spinal Muscular Atrophy Drug

Kimberly Redmond | Equities.com |

Swiss drugmaker Novartis AG will launch a new phase three study to expand the use of Zolgensma — the world’s most expensive medicine — following the US Food and Drug Administration’s (FDA) decision to lift a halt on clinical trials.

On Tuesday, Novartis said it plans to study the use of the gene therapy for for the treatment of spinal muscular atrophy (SMA) in patients between the ages of 2 and 18.


Pfizer-BioNTech COVID-19 Vaccine Shows at Least Six Months of Protection in Ongoing Study

Kimberly Redmond | Equities.com |

Newly-released data from an ongoing study of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shows the two-dose shot offered high levels of protection for at least six months after administration.

On Thursday, the companies released updated topline results from their Phase 3 trial, which found the vaccine had 91.3% efficacy against the virus, and said they plan to apply for full approval from the US Food and Drug Administration. Currently, all of the vaccines in use in the US have only Emergency Use Authorization (EUA) from the FDA.


COVID-19 Vaccines Being Tested in Younger Children

AP News | Equities.com |

The 9-year-old twins didn’t flinch as each received test doses of Pfizer’s COVID-19 vaccine -- and then a sparkly bandage to cover the spot.

“Sparkles make everything better,” declared Marisol Gerardo as she hopped off an exam table at Duke University to make way for her sister Alejandra.

Researchers in the U.S. and abroad are beginning to test younger and younger kids to make sure COVID-19 vaccines are safe and work for each age. The first shots are going to adults who are most at risk from the coronavirus, but ending the pandemic will require vaccinating children too.


AstraZeneca's Missteps Could Harm Long-Term Credibility of Its COVID-19 Vaccine

AP News | Equities.com |

Image source: Gencat, CC0, via Wikimedia Commons

By MARIA CHENG

LONDON (AP) — AstraZeneca’s repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say.

The latest stumble fo...


AstraZeneca Reports Its Vaccine Is 79% Effective at Preventing Symptomatic COVID-19

AP News | Equities.com |

WASHINGTON (AP) — AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 — including in older adults. There were no severe illnesses or hospitalizations among vaccinated volunteers, compared with five such cases in participants who received dummy shots — a small number, but consistent with findings from Britain and other countries that the vaccine protects against the worst of the disease.


Johnson & Johnson Says Its One-Shot Vaccine Has 85% Efficacy in Preventing Severe COVID-19 Disease

Kimberly Redmond | Equities.com |

Johnson & Johnson said findings from its late-stage clinical trial shows its COVID-19 vaccine completely protects against coronavirus-related hospitalization and death a month after vaccination.

Phase 3 trial data released Friday showed Johnson & Johnson’s single-dose vaccine is 66% effective at preventing moderate to severe illness and 85% protective against the most serious symptoms.


Johnson & Johnson COVID-19 Vaccine Shows Promise in Early Stage Trial After One Shot

Kimberly Redmond | Equities.com |

Johnson & Johnson says data from its early-stage COVID-19 vaccine trials shows that nearly all participants had immunity after just one shot, giving the pharmaceutical company confidence its immunization is just as effective as the double-dose manufactured by Moderna and Pfizer.

According to a report published Wednesday in The New England Journal of Medicine, over 90% of the 800 participants developed neutralizing antibodies 29 days after a single dose of the experimental vaccine and the levels of these antibodies stayed stable for at least 71 days after injection.


Pharmaceutical Companies Raise Prices on More Than 500 Drugs To Start 2021

Reuters | Equities.com |

Drugmakers including Abbvie Inc and Bristol Myers Squibb raised U.S. list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn.

The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price-cutting rules from the Trump administration, which would reduce the industry’s profitability.

They include more than 300 price increases from companies like Pfizer and GlaxoSmithKline reported by Reuters late last week.


Sponsored Financial Content

Market Movers